- Home
- BBIO vs RVMD Comparison
BBIO vs RVMD Comparison
Compare BBIO & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- RVMD
- Stock Information
- Founded
- BBIO 2015
- RVMD 2014
- Country
- BBIO United States
- RVMD United States
- Employees
- BBIO N/A
- RVMD N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBIO Health Care
- RVMD Health Care
- Exchange
- BBIO Nasdaq
- RVMD Nasdaq
- Market Cap
- BBIO 8.0B
- RVMD 7.5B
- IPO Year
- BBIO 2019
- RVMD 2020
- Fundamental
- Price
- BBIO $42.78
- RVMD $36.98
- Analyst Decision
- BBIO Strong Buy
- RVMD Strong Buy
- Analyst Count
- BBIO 14
- RVMD 12
- Target Price
- BBIO $58.85
- RVMD $68.67
- AVG Volume (30 Days)
- BBIO 3.3M
- RVMD 3.1M
- Earning Date
- BBIO 07-31-2025
- RVMD 08-06-2025
- Dividend Yield
- BBIO N/A
- RVMD N/A
- EPS Growth
- BBIO N/A
- RVMD N/A
- EPS
- BBIO N/A
- RVMD N/A
- Revenue
- BBIO $127,415,000.00
- RVMD N/A
- Revenue This Year
- BBIO $102.05
- RVMD N/A
- Revenue Next Year
- BBIO $54.69
- RVMD $241.39
- P/E Ratio
- BBIO N/A
- RVMD N/A
- Revenue Growth
- BBIO N/A
- RVMD N/A
- 52 Week Low
- BBIO $21.72
- RVMD $29.17
- 52 Week High
- BBIO $45.48
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- BBIO 62.54
- RVMD 38.51
- Support Level
- BBIO $39.65
- RVMD $36.61
- Resistance Level
- BBIO $45.48
- RVMD $40.70
- Average True Range (ATR)
- BBIO 1.56
- RVMD 1.54
- MACD
- BBIO 0.15
- RVMD -0.44
- Stochastic Oscillator
- BBIO 60.90
- RVMD 7.43
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.